Randomized, Placebo-Controlled, Single-Ascending-Dose Study of BMS-791325, a Hepatitis C Virus (HCV) NS5B Polymerase Inhibitor, in HCV Genotype 1 Infection

Preclinical Characterization of BMS-791325, an Allosteric Inhibitor of Hepatitis C Virus NS5B Polymerase

(2014) Julie A. Lemm et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C: results from a US database of over 45 000 HCV-infected, evaluated patients

(2013) A. H. Talal et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection

(2013) Gregory T. Everson et al.   GASTROENTEROLOGY

Effect on Hepatitis C Virus Replication of Combinations of Direct-Acting Antivirals, Including NS5A Inhibitor Daclatasvir

(2012) Lenore A. Pelosi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

1194 CHARACTERIZATION OF VIRAL ESCAPE IN HCV GENOTYPE 1-INFECTED PATIENTS TREATED WITH BMS-791325 AND PEGYLATED INTERFERON-ALFA AND RIBAVIRIN

(2012) D. McPhee et al.   JOURNAL OF HEPATOLOGY

Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin

(2012) Dominique Larrey et al.   JOURNAL OF HEPATOLOGY

1163 A PHASE 2A STUDY OF BMS-791325, AN NS5B POLYMERASE INHIBITOR, WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION

(2012) H. Tatum et al.   JOURNAL OF HEPATOLOGY

The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus Genotype 1 Infection, But With Issues Still Pending

(2011) Jean–Michel Pawlotsky   GASTROENTEROLOGY

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

(2011) Marc G. Ghany et al.   HEPATOLOGY

EASL Clinical Practice Guidelines: Management of hepatitis C virus infection

(2011)   JOURNAL OF HEPATOLOGY

New NS5B polymerase inhibitors for hepatitis C

(2010) Florence Legrand-Abravanel et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study

(2010) Andri Rauch et al.   GASTROENTEROLOGY

Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: A review of the last 20 years (1989–2009)

(2009) Marie-Pierre de Béthune   ANTIVIRAL RESEARCH

The global burden of hepatitis C

(2009) Daniel Lavanchy   LIVER INTERNATIONAL

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

(2009) Dongliang Ge et al.   NATURE

IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy

(2009) Vijayaprakash Suppiah et al.   NATURE GENETICS

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity In Vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus

(2008) Norman M. Kneteman et al.   HEPATOLOGY

Diagnosis, management, and treatment of hepatitis C: An update

(2008) Marc G. Ghany et al.   HEPATOLOGY